Your browser doesn't support javascript.
loading
A Novel EGFRvIII T-Cell Bispecific Antibody for the Treatment of Glioblastoma.
Iurlaro, Raffaella; Waldhauer, Inja; Planas-Rigol, Ester; Bonfill-Teixidor, Ester; Arias, Alexandra; Nicolini, Valeria; Freimoser-Grundschober, Anne; Cuartas, Isabel; Martínez-Moreno, Alba; Martínez-Ricarte, Francisco; Cordero, Esteban; Cicuendez, Marta; Casalino, Simona; Guardia-Reyes, Xavier; Fahrni, Linda; Pöschinger, Thomas; Steinhart, Virginie; Richard, Marine; Briner, Stefanie; Mueller, Joerg; Osl, Franz; Sam, Johannes; Colombetti, Sara; Bacac, Marina; Klein, Christian; Pineda, Estela; Reyes-Figueroa, Luis; Di Somma, Alberto; González, Josep; Nuciforo, Paolo; Carles, Joan; Vieito, Maria; Tabernero, Josep; Umaña, Pablo; Seoane, Joan.
Affiliation
  • Iurlaro R; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Waldhauer I; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Planas-Rigol E; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Bonfill-Teixidor E; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Arias A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Nicolini V; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Freimoser-Grundschober A; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Cuartas I; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martínez-Moreno A; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Martínez-Ricarte F; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Cordero E; Universitat Autònoma de Barcelona, Cerdanyola del Vallès, Spain.
  • Cicuendez M; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Casalino S; Vall d'Hebron Institut de Recerca (VHIR), Vall d'Hebron University Hospital, Barcelona, Spain.
  • Guardia-Reyes X; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Fahrni L; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Pöschinger T; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Steinhart V; Roche Innovation Center Munich (RICM), Roche Pharma Research and Early Development (pRED), Penzberg, Germany.
  • Richard M; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Briner S; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Mueller J; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Osl F; Roche Innovation Center Munich (RICM), Roche Pharma Research and Early Development (pRED), Penzberg, Germany.
  • Sam J; Roche Innovation Center Munich (RICM), Roche Pharma Research and Early Development (pRED), Penzberg, Germany.
  • Colombetti S; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Bacac M; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Klein C; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Pineda E; Roche Innovation Center Zurich (RICZ), Roche Pharma Research and Early Development (pRED), Schlieren, Switzerland.
  • Reyes-Figueroa L; Hospital Clinic, University of Barcelona and Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Di Somma A; Department of Neurosurgery Hospital Clinic Barcelona, IDIBAPS Advances in Neurosurgery Research Group, Barcelona, Spain.
  • González J; Department of Neurosurgery Hospital Clinic Barcelona, IDIBAPS Advances in Neurosurgery Research Group, Barcelona, Spain.
  • Nuciforo P; Department of Neurosurgery Hospital Clinic Barcelona, IDIBAPS Advances in Neurosurgery Research Group, Barcelona, Spain.
  • Carles J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Vieito M; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Tabernero J; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Umaña P; Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Seoane J; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
Mol Cancer Ther ; 21(10): 1499-1509, 2022 10 07.
Article in En | MEDLINE | ID: mdl-35915983
Subject(s)
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Antibodies, Bispecific / Glioblastoma Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2022 Document type: Article Affiliation country: Spain Country of publication: United States
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Brain Neoplasms / Antibodies, Bispecific / Glioblastoma Type of study: Prognostic_studies Limits: Animals / Humans Language: En Journal: Mol Cancer Ther Journal subject: ANTINEOPLASICOS Year: 2022 Document type: Article Affiliation country: Spain Country of publication: United States